Minutes: confirmed

Guideline Development Group Meeting: ACS, GDG 6

Date and Time: Wilan room, 10.30-4.30pm, Thursday 2nd October 2008

Place: National Collaborating Centre for Chronic Conditions
Royal College of Physicians
11 St Andrew’s Place
Regent’s Park
London
NW1 4LE

Present:

GDG members
John Camm GDG Chair
Huon Gray Clinical Advisor
Sotiris Antoniou Pharmacy representative
Rob Henderson Cardiologist representative
Kate Lovibond NCC-CC health economist
Gavin Maxwell Patient and carer representative
Francis Morris A&E Physician representative
Claire Turner NCC-CC Senior Project Manager (minutes)
Richard Underwood Cardiac imaging representative
David Geldard Patient and Carer representative
Mark de Belder Cardiologist representative
Emily Crowe NCC-CC Research fellow
Alun Roebuck Nurse Representative
David Taggart Surgical representative (invited expert)
Mark Whitbread Paramedic representative
Marjan Jahangiri Surgical representative
Jenny Cadman CCU nurse representative
Jill Parnham NCC-CC assistant director (operations) from ~1pm onwards

Notes

Welcome

1. JC welcomed everyone to the group. JC welcomed Marjan Jahangiri as the surgical representative for the group. Apologies were received from Susan Latchem. The declarations of interests register was made available to the GDG chair. The chair requested updates to the existing declarations of interests from GDG members. JC declared that he is going to give a talk for Servier on anti-anginal drugs and gave a talk last week on anti-anginal drugs for Bristol Myers Squibb. SA informed the group that he had attended an advisory board on behalf of Sanofi Aventis.
Notes

2. The GDG discussed the clinical and health economic evidence tables and statements, and formulate recommendations for the following:

   In adults with UA or non-ST elevation MI, for which patients does CABG improve outcomes in comparison with PCI or non-invasive treatment?

3. The minutes of GDG5 were reviewed by the group. The minutes of the meeting were agreed as an accurate record, however a small number of typographical changes were made

4. Draft clinical guideline. The group reviewed the ANGIO and RISK sections of the guideline.

5. Health economic work plan - KL presented the model outline, the economic evaluation type, population, time horizon, comparators and the approach to modelling was agreed by the group. The data sources were discussed by the group. The group discussed that there were some limitations using registry data.

   - HE subgroup notes
   KL presented the HE subgroup teleconference meeting 2 notes to the group. The group accepted the notes of the meeting. The GDG signed up to the drugs model. Defining risk is a critical component to the model which we will be discussing at the next meeting.

6. Any other business

   - Clinical questions schedule
   CT informed the group that a couple of GDG members noted that they were unable to attend GDG9 meeting scheduled for 18\textsuperscript{th} December 2008. CT informed the group that if the group wished to move the date the only other possible the meeting could be moved to is the 17\textsuperscript{th} December 2008. CT asked the group to send her an email informing her which date is the most preferred option. The date of the meeting will be based on this decision.

   **Action:** GDG members to inform CT which GDG9 date is preferred.

   - RISK1
   CT informed the group that risk had been moved to the next GDG for discussion as it was important to get resolution across the recommendations with regards to RISK. CT noted that she had invited Keith Fox to attend the meeting and that HG and CT would write to Keith Fox outlining the issues surrounding RISK.

**Next meeting:** GDG meeting (GDG7), 30th Oct 2008, 10:30 – 16:00, Henry Cohen, Jerwood Education Centre, RCP